Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IGEN v. Roche

This article was originally published in The Gray Sheet

Executive Summary

Maryland federal appeals court affirms a 1998 preliminary injunction against Roche Diagnostics Jan. 4, enjoining the firm from marketing IGEN's Origen technology under a 1992 licensing agreement to physician office laboratories (POL), which IGEN claims Roche violated. Under the injunction, Roche is required to turn over all POL customers to IGEN and escrow all POL sales. Estimating that Roche has 200-300 POL customers generating in excess of $10 mil. in annual sales, IGEN alleges that Roche's reported $7.4 mil in escrow from 100 POL customers "does not represent all of the revenue required to be placed in escrow"

You may also be interested in...

Roche Sees Minimal Elecsys Financial Impact In Wake Of IGEN Court Order

Roche Diagnostics expects only a "small percentage" of its Elecsys line of immunoassay analyzers incorporating IGEN's Origen technology will be affected by an upcoming court-ordered transfer of Elecsys physician office laboratory accounts to IGEN.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts